Acer gains on resubmission of genetic disorder drug application

Acer Therapeutics

18/07/2022 15:58

** Shares of Acer Therapeutics  ACER.O  jump as much as 6.5%
to $1.63 - set for their second straight session of gains 
    ** Drug developer says it has resubmitted its application to
the U.S. health regulator, seeking marketing approval for
ACER-001 as a treatment for urea cycle disorders (UCD)
 urn:newsml:reuters.com:*:nGNX8d2ClT 
    ** In June, the Food and Drug Administration had declined to
approve ACER-001, citing a need to inspect third-party contract
packaging manufacturer  urn:newsml:reuters.com:*:nGNX1BcYcY 
    ** Co says notified the FDA that its third-party
manufacturer is ready for inspection
    ** Co believes resubmitted application addresses all 
concerns raised by the regulator 
    ** UCDs are caused by genetic mutations and affect how a
body removes the waste made from breaking down protein
    ** Up to Friday's close, ACER down ~32% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))